Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS Med, 21
Mismanagement of Patients with High Altitude Illness Evacuated from the Mount Everest Region in Nepal.
Pant SR. et al, (2024), High Alt Med Biol
A retrospective investigation of the population structure and geospatial distribution of Salmonella Paratyphi A in Kathmandu, Nepal.
Mylona E. et al, (2024), PLoS Negl Trop Dis, 18
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Demographics Collaborators None., (2024), Lancet, 403, 1989 - 2056
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Causes of Death Collaborators None., (2024), Lancet, 403, 2100 - 2132
The facilitators of and barriers to antimicrobial use and misuse in Lalitpur, Nepal: a qualitative study.
Udas S. et al, (2024), BMC Public Health, 24
High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.
Peto L. et al, (2024), Lancet, 403, 1339 - 1340
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Bijukchhe SM. et al, (2024), Vaccine, 42, 2018 - 2025
The Identification of Enteric Fever-Specific Antigens for Population-Based Serosurveillance.
Mylona E. et al, (2024), J Infect Dis, 229, 833 - 844
Estimating the subnational prevalence of antimicrobial resistant Salmonella enterica serovars Typhi and Paratyphi A infections in 75 endemic countries, 1990-2019: a modelling study.
GRAM Typhoid Collaborators None., (2024), Lancet Glob Health, 12, e406 - e418
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914